Holen Sie sich die Stockscreener-App
25.66
0.75%
0.19
Handel nachbörslich:
25.80
0.14
+0.55%
Schlusskurs vom Vortag:
$25.47
Offen:
$25.54
24-Stunden-Volumen:
12.21M
Relative Volume:
1.17
Marktkapitalisierung:
$9.98B
Einnahmen:
$3.14B
Nettoeinkommen (Verlust:
$-3.36B
KGV:
-2.9393
EPS:
-8.73
Netto-Cashflow:
$-4.03B
1W Leistung:
-6.59%
1M Leistung:
-23.72%
6M Leistung:
-15.97%
1J Leistung:
-68.43%
1-Tages-Spanne:
$25.32
$26.26
1-Wochen-Bereich:
$25.30
$27.48
52-Wochen-Spanne:
$23.15
$91.99
Moderna Inc Stock (MRNA) Company Profile
Firmenname
Moderna Inc
Sektor
Branche
Telefon
(617) 714-6500
Adresse
325 BINNEY STREET, CAMBRIDGE
Vergleichen Sie MRNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
25.66 | 9.91B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-13 | Eingeleitet | Citigroup | Neutral |
| 2025-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Herabstufung | Goldman | Buy → Neutral |
| 2024-12-18 | Herabstufung | Argus | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-19 | Eingeleitet | Berenberg | Hold |
| 2024-11-18 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-09-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Herabstufung | Jefferies | Buy → Hold |
| 2024-09-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-11-03 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-06-26 | Hochstufung | UBS | Neutral → Buy |
| 2023-04-26 | Eingeleitet | Guggenheim | Neutral |
| 2023-03-13 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-02-24 | Herabstufung | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Hochstufung | Jefferies | Hold → Buy |
| 2022-12-14 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2022-01-26 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Eingeleitet | UBS | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Sell |
| 2021-10-15 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Bestätigt | Jefferies | Hold |
| 2021-02-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Herabstufung | Needham | Buy → Hold |
| 2020-11-23 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-11-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-07-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Argus | Buy |
| 2020-06-08 | Eingeleitet | Barclays | Overweight |
| 2020-04-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-05 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Moderna Inc Aktie (MRNA) Neueste Nachrichten
Moderna, Teleflex, Envista, Enovis, and UnitedHealth Shares Are Soaring, What You Need To Know - TradingView
CDC Shooting Linked To Suspect's COVID-19 Vaccine Beliefs, Former Staff Blame RFK Jr. Hostility Toward Agency - Benzinga
Mitsubishi UFJ Asset Management Co. Ltd. Grows Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Vanguard Group Inc. Boosts Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. (MRNA)’s “Got The Double Whammy,” Says Jim Cramer - MSN
Day 5 of Loss Streak for Moderna Stock with -7.9% Return (vs. -39% YTD) [8/11/2025] - Trefis
Moderna, Inc. (MRNA) stock price, news, quote and history - uk.finance.yahoo.com
FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply - Benzinga
Global and U.S. Personalized Cancer Vaccines Market Generated - openPR.com
Global Cancer Vaccines Market to Surpass USD 15.00 Billion by 2032, Unlocking Over USD 10 Billion in New Growth Opportunities | MarketsandMarkets™. - GlobeNewswire Inc.
The 3 Things That Matter for Moderna Now - AOL.com
ASR Vermogensbeheer N.V. Buys Shares of 21,647 Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Is Moderna Inc. gaining market shareGame-Changing Investment Alerts - mustnews.co.kr
Research Analysts Offer Predictions for Moderna Q3 Earnings - MarketBeat
54,198 Shares in Moderna, Inc. (NASDAQ:MRNA) Acquired by ABC Arbitrage SA - MarketBeat
Envestnet Asset Management Inc. Sells 12,212 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
IBM and Moderna have simulated the longest mRNA pattern without AI — they used a quantum computer instead - Live Science
LPL Financial LLC Grows Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
UTMB, Moderna hit with vaccine research cancellation month after publishing new mRNA data - The Business Journals
Moderna to Cut 10% of Staff to Offset Slowing Covid Business - MSN
OVERSEA CHINESE BANKING Corp Ltd Has $1.16 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
XTX Topco Ltd Purchases 27,237 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Is Cutting 10,000 Jobs as Its Business Erodes. How Should You Play MRNA Stock Here? - Barchart.com
Is Moderna Stock A Sell After Cutting Its Sales Outlook — Again? - Investor's Business Daily
Moderna to slash 10% of workforce as biotech cuts costs, Covid shot sales slow - MSN
Moderna, Inc. (NASDAQ:MRNA) Shares Acquired by Banco Santander S.A. - MarketBeat
Moors & Cabot Inc. Reduces Stake in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
RFK Jr. ends mRNA vaccine support; Moderna, other Mass. firms affected - WCVB
US HHS cancels 22 BARDA mRNA vaccine contracts - BioWorld MedTech
Public health experts dismayed by RFK Jr.'s defunding of mRNA vaccine research : ShotsHealth News - NPR
Moderna’s stock takes a hit as RFK Jr. backs out of some mRNA vaccine deals - MSN
HHS abandons mRNA vaccine research - BioPharma Dive
US health agency to wind down mRNA vaccine development - Reuters
The intrapreneur edge: What we learned at Moderna about the need to act like a startup - The Globe and Mail
Robust Growth in Mrna Therapeutics Process Development Market - openPR.com
Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1 - Amarillo Globe-News
RFK Jr. Axes 22 mRNA Vaccine Projects Under BARDA - BioSpace
HHS halts funding for mRNA vaccine activities (MRNA:NASDAQ) - Seeking Alpha
RFK Jr. Halts $500 Million In mRNA Vaccine Projects Backed By Pfizer, Moderna: 'We're Prioritizing Safer, Broader Strategies' - Benzinga
Moderna Stock: Is Wall Street Bullish or Bearish? - Yahoo Finance
Banque Cantonale Vaudoise Buys Shares of 14,589 Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Finanzdaten der Moderna Inc-Aktie (MRNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.91%
3.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):